Abstract
The constantly growing volume of available data on cardiovascular disorders will require an organized interpretation of variations in DNA and mRNA as well as proteins, both on the individual and the population levels. A five-step strategy can be followed when trying to identify genes and gene products involved in differential responses to cardiovascular drugs (Siest et al. 2007): Pharmacokinetic-related genes and phenotypes Pharmacodynamic targets, genes, and products Cardiovascular diseases and risks depending on specific or large metabolic cycles Physiological variations of previously identified genes and proteins Environmental influences on them
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arking DE, Pfeufer A, Post W et al (2006) A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genetics 38:644–651
Caulfield M, Munroe P, Pembroke J et al (2003) Genome-wide mapping of human loci for essential hypertension. Lancet 361:2118–2123
Chasman DI, Posada D, Subrahmanyan L et al (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291:2821–2827
Couvert P, Giral P, Dejager S et al (2008) Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9:1217–1227
Gage BF, Eby C, Milligan PE et al (2004) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91:87–94
Hakonarson H, Thorvaldsson S, Helgadottir A et al (2005) Effects of a 5-Lipoxygenase–Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial Infarction: A Randomized Trial. JAMA 293:2245–2256
Johnson JA, Boerwinkle E, Zineh I et al (2009) Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 157:442–449
Judson R, Brain C, Dain B et al (2004) New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis 177:345–351
Kathiresan S, Melander O, Anevski D et al (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358:1240–1249
Koenig W, Khuseyinova N, Lowel H et al (2004) Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110:1903–1908
Kunnas TA, Ilveskoski E, Niskakangas T et al (2002a) Association of the endothelial nitric oxide synthase gene polymorphism with risk of coronary artery disease and myocardial infarction in middle-aged men. J Mol Med 80:605–609
Kunnas TA, Lehtimaki T, Laaksonen R et al (2002b) Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study. J Mol Med 80:802–807
Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 103:11288–11293
Siest G, Marteau JB, Maumus S et al (2007) Pharmacogenomics and pharmacoproteomics: a strategy for cardio-vascular drugs. Ann Pharm Fr 65:203–210
Taylor AL, Ziesche S, Yancy C et al (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. NEJM 351:2049–2057
Terra SG, Pauly DF, Lee CR et al (2005) Beta-adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 77:127–137
Voora D, Shah SH, Reed CR et al (2008) Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circulation Cardiovasc Genet 1:100–106
Wickline SA, Neubauer AM, Winter P et al (2006) Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 26:435–441
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Jain, K.K. (2009). Personalized Therapy of Cardiovascular Diseases. In: Textbook of Personalized Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0769-1_12
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0769-1_12
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0768-4
Online ISBN: 978-1-4419-0769-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)